ITOSiTeos Therapeutics, Inc.

Nasdaq iteostherapeutics.com


$ 16.00 $ 0.00 (0 %)    

Wednesday, 11-Sep-2024 15:59:53 EDT
QQQ $ 468.28 $ 9.96 (2.17 %)
DIA $ 409.73 $ 1.01 (0.25 %)
SPY $ 554.79 $ 5.63 (1.03 %)
TLT $ 100.61 $ -0.08 (-0.08 %)
GLD $ 232.25 $ -0.37 (-0.16 %)
$ 15.99
$ 15.96 x 100
-- x --
-- - --
$ 8.20 - $ 18.75
775,490
na
583.98M
$ 0.81
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-10-2024 03-31-2024 10-Q
3 03-06-2024 12-31-2023 10-K
4 11-07-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-10-2023 03-31-2023 10-Q
7 03-15-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-10-2022 06-30-2022 10-Q
10 05-12-2022 03-31-2022 10-Q
11 03-23-2022 12-31-2021 10-K
12 11-10-2021 09-30-2021 10-Q
13 08-11-2021 06-30-2021 10-Q
14 05-13-2021 03-31-2021 10-Q
15 03-24-2021 12-31-2020 10-K
16 11-12-2020 09-30-2020 10-Q
17 09-01-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 wells-fargo-initiates-coverage-on-iteos-therapeutics-with-overweight-rating-announces-price-target-of-31

Wells Fargo analyst Eva Fortea Verdejo initiates coverage on ITeos Therapeutics (NASDAQ:ITOS) with a Overweight rating and a...

 jp-morgan-maintains-overweight-on-iteos-therapeutics-lowers-price-target-to-24

JP Morgan analyst Brian Cheng maintains ITeos Therapeutics (NASDAQ:ITOS) with a Overweight and lowers the price target from ...

Core News & Articles

This event has triggered $35 million in development milestone payments from GSK, its partner for belrestotug. iTeos and GSK en...

Core News & Articles

iTeos Therapeutics, Inc. (NASDAQ:ITOS) ("iTeos"), a clinical-stage biopharmaceutical company pioneering the discovery a...

 hc-wainwright--co-maintains-buy-on-iteos-therapeutics-raises-price-target-to-46

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains ITeos Therapeutics (NASDAQ:ITOS) with a Buy and raises the ...

Core News & Articles
Market-Moving News for May 10th
05/10/2024 12:41:27

ITOS: 39% | iTeos Therapeutics shares are trading higher after the company announced a $120 million registered direct offering ...

 iteos-therapeutics-q1-2024-gaap-eps-107-misses-102-estimate

ITeos Therapeutics (NASDAQ:ITOS) reported quarterly losses of $(1.07) per share which missed the analyst consensus estimate of ...

 jp-morgan-maintains-overweight-on-iteos-therapeutics-lowers-price-target-to-27

JP Morgan analyst Brian Cheng maintains ITeos Therapeutics (NASDAQ:ITOS) with a Overweight and lowers the price target from ...

 hc-wainwright--co-reiterates-buy-on-iteos-therapeutics-maintains-44-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates ITeos Therapeutics (NASDAQ:ITOS) with a Buy and maintains ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION